Contractors may benefit from £500m GlaxoSmithKline investment 1334233663
Contractors may benefit from £500m GlaxoSmithKline investment
Those working through an umbrella company in the pharmaceutical sector, may find an increased number of job opportunities are made available due to Britain’s biggest drug maker announcing it will invest more than £500m in the UK.
The company, GlaxoSmithKline (GSK), has predicted that this investment across its manufacturing sites, will create a further 1,000 jobs in the UK, many being made available for those working as an umbrella company contractor.
The company announced Ulverston in Cumbria as the location for the first new GSK manufacturing facility to be built in the UK for almost 40 years. Investment will also be made at the company’s two manufacturing sites in Scotland at Montrose and Irvine.
Umbrella company contractors in the pharmaceutical industry, will be pleased to hear that these investments represent one of the largest commitments to the UK life-sciences sector in recent years.
The recent tax incentives announced in the Budget are the reasons behind the massive investment, as the Chancellor revealed that the government will decrease the amount of corporation tax charged on profits generated from UK-owned intellectual property.
GSK’s CEO Sir Andrew Witty said, “We can confirm that we will build GSK’s first new UK factory for almost 40 years and that we will make other substantial capital investments in our British manufacturing base. In total, this will create up to 1,000 new jobsover the lifetime of the projects.
“We are also actively considering other investments in our UK manufacturing network which would create further jobs and reinforce the UK’s international competitiveness and as a world leader in life sciences.”